In addition to the conditions mentioned above, a wide range of other mental disorders, including Post-Traumatic Stress Disorder (PTSD), have also been shown to respond less effectively to pharmaceutical treatments as well.But now, for the first time, a presidential administration appears poised to give them a try — in the name of mental health.Trump officials (and nominees) that have expressed an interest in utilizing psychedelics for mental health issues:Robert F. Kennedy Jr. – Secretary of Health and Human ServicesDoug Collins – Secretary of Veterans AffairsDr. Casey Means – Trump Nominee for U.S. Surgeon GeneralMarty Makary – FDA Commissioner“This line of therapeutics has tremendous advantage if given in a clinical setting and we are working very hard to make sure that happens within 12 months,” Kennedy Jr. (RFK Jr.) told members of Congress.The announcement coincides with a growing embrace of psychedelics in traditionally conservative strongholds like Texas, where former Trump cabinet member and former Texas Governor Rick Perry has emerged as a vocal advocate.to shift that narrative and build a national movement to loosen restrictions and expand access to scientific research.“Governmental systems move slowly and inefficiently,” said Bryan Hubbard of Americans for Ibogaine, a group formed with Perry. “Sometimes you find yourself constrained in terms of the progress you can make from within.”Ibogaine stands apart from other psychedelics due to its distinctive combination of potential benefits and risks. Limited studies and anecdotal evidence indicate that the drug may significantly alleviate addiction and trauma. It was even marketed for medical use in France for several decades beginning in the 1930s. However, ibogaine also carries some safety concerns, including the risk of dangerous cardiac arrhythmias, which can be fatal if not promptly addressed.After 13 years as a Navy SEAL, a man named Marcus Capone, who spoke to the press, says that he grappled with intense anger, insomnia, and mood swings. In 2017, prompted by his wife Amber’s encouragement, he decided to try ibogaine as a last resort. He described his initial ibogaine experience as “a complete purge of everything.”“Afterward I felt the weight just completely off my shoulders,” he said. “No more anxiety, no more depression, life made sense all of a sudden.”A nonprofit established by the Capones, Veterans Exploring Treatment Solutions (VETS), has assisted over 1,000 veterans in traveling abroad to access ibogaine and other psychedelic treatments.Nonetheless, federal scientists already previously examined ibogaine—three decades ago, as the National Institute on Drug Abuse funded early research into its potential as an addiction therapy. However, that line of inquiry was halted after the studies revealed concerns over “cardiovascular toxicity.”“It would be dead in the water,” in regard to receiving FDA approval, according to longtime NIDA director Nora Volkow.However, Volkow emphasized that her agency continues to show interest in psychedelics, including ibogaine, and is currently funding a U.S. pharmaceutical company developing a “safer, synthetic version” of the drug.“I am very intrigued by their pharmacological properties and how they are influencing the brain,” Volkow said. “But you also have to be very mindful not to fall into the hype and to be objective and rigorous in evaluating them.”